Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Change in Cash: 2019-2025

Historic Change in Cash for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to -$184.1 million.

  • Revolution Medicines' Change in Cash fell 146.74% to -$184.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year increase of 111.59%. This contributed to the annual value of -$152.4 million for FY2024, which is 128.43% down from last year.
  • Per Revolution Medicines' latest filing, its Change in Cash stood at -$184.1 million for Q3 2025, which was down 366.35% from $69.1 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Change in Cash registered a high of $342.6 million during Q4 2024, and its lowest value of -$407.7 million during Q1 2024.
  • Over the past 3 years, Revolution Medicines' median Change in Cash value was -$22.1 million (recorded in 2023), while the average stood at $5.4 million.
  • Over the last 5 years, Revolution Medicines' Change in Cash had its largest YoY gain of 2,554.39% in 2023, and its largest YoY loss of 667.35% in 2023.
  • Over the past 5 years, Revolution Medicines' Change in Cash (Quarterly) stood at -$20.0 million in 2021, then increased by 12.37% to -$17.5 million in 2022, then surged by 2,030.45% to $338.4 million in 2023, then grew by 1.25% to $342.6 million in 2024, then tumbled by 146.74% to -$184.1 million in 2025.
  • Its Change in Cash was -$184.1 million in Q3 2025, compared to $69.1 million in Q2 2025 and -$209.5 million in Q1 2025.